All In Biotech

Drug Trial Radar · NCT07756736

Psilocybin Therapy for Methamphetamine Use Disorder and HIV

Psilocybin Recovery Intervention for Stopping Methamphetamine Use

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Apr 2029

Study completion Jun 2029

Sponsor

Lead sponsor
Nicky Mehtani, MD, MPHAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Drug Abuse (NIDA)
First posted
Aug 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 25 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn whether it is possible to use psilocybin in combination with motivational support therapy to treat moderate-to-severe methamphetamine use disorder (MeUD) in people with HIV who are seeking to stop using methamphetamine. The main questions it aims to answer are: * Do people with HIV and MeUD find psilocybin with motivational support therapy feasible and acceptable as a potential treatment? * Is psilocybin safe and tolerable among people with HIV and MeUD? Participants will: * Be randomly assigned to receive a single monitored dose of either 25 mg (higher dose) or 5 mg (lower dose) psilocybin * Have 3 preparation and 3 integration motivational support therapy visits before and after the psilocybin dosing session. * Report their methamphetamine use prior to, during, and up to 3 months following the intervention * Optionally receive one additional open-label 25 mg psilocybin session after the 4-week assessment, if eligible

Conditions

  • Methamphetamine Use Disorder
  • Human Immunodeficiency Virus (HIV)

Interventions

  • Psilocybin 5 mgDrug

    Single oral 5 mg dose of psilocybin, administered as a capsule under direct observation during a monitored \~8-hour dosing session. Serves as the low-dose active control during the double-blind randomized phase.

  • Psilocybin 25 mgDrug

    Single oral 25 mg dose of psilocybin, administered as a capsule under direct clinical observation during a monitored \~8-hour dosing session. Given as the higher dose during the double-blind randomized phase and as the dose used in the optional open-label session.

  • Motivational SupportBehavioral

    Manualized motivational support delivered by trained facilitators, adapted from the NIAAA Project MATCH MET manual. During the double-blind phase, participants attend 3 preparatory talk therapy sessions before dosing and 3 integration talk therapy sessions after dosing; the optional open-label session is accompanied by an additional 1 preparatory and 3 integration talk therapy sessions before and after the second (open-label) dose. Sessions support rapport, intention-setting, psilocybin psychoeducation and safety, and post-session meaning-making.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recruitment EfficiencyTime frame: Screening to Baseline (approximately 35 days)
  2. Dosing CompletionTime frame: Baseline to Dosing Visit (approximately 10 days)
  3. RetentionTime frame: Dosing Visit to Visit 9 (approximately 28 days)
  4. AcceptabilityTime frame: Visit 9, approximately 38 days
  5. Adverse EventsTime frame: Dosing Visit to Visit 9 (approximately 28 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UCSF at Zuckerberg San Francisco General Hospital

    San Francisco, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.